From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial
Group
RCB
0
n (%)
I
II
III
Control n = 27
8 (29.6)
2 (7.4)
6 (22.2)
11 (40.7)
Intervention n = 25
8 (32.0)
2 (8.0)
5 (20.0)
10 (40.0)
Total n = 52
16 (30.8)
4 (7.7)
11 (21.2)
21 (40.4)